Core Viewpoint - The price of Pianzaihuang, once dubbed the "Moutai of medicine," has significantly decreased from a peak of 1600 yuan per pill to around 590 yuan on e-commerce platforms, indicating a collapse of the speculative bubble surrounding the product [1] Group 1: Market Dynamics - Pianzaihuang's price drop reflects a return to the essence of medicine, emphasizing its therapeutic role rather than being treated as a speculative investment [1] - The product's price decline is attributed to the disillusionment with its perceived health benefits, which were exaggerated on social media, leading to a misalignment with its actual medical purpose [1] Group 2: Regulatory and Consumer Implications - The revised Drug Administration Law of the People's Republic of China emphasizes that drug management should focus on safeguarding public health and not allow drugs to become speculative commodities [2] - Pharmaceutical companies are urged to maintain their commitment to pharmaceutical services and resist the temptation to engage in market speculation [2] - Consumers are advised to make rational choices regarding medications, avoiding the pitfalls of following trends or hoarding based on perceived scarcity [2]